

LITERATURA

1. Ferlay J, Ervik M, Colombet M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.fr/today>. Published 2022. Accessed May 19, 2024.
2. Krejčí D, Mužík J, Dušek L. Novotvary 2019–2021 ČR. Available from: www.uzis.cz.
3. Smyth EC, Nilsson M, Grabsch HJ, et al. Gastric cancer. *Lancet*. 2020;396(10251):635–648. doi: 10.1016/S0140-6736(20)31288-5. PMID: 32861308.
4. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol*. 2006;24(18):2903–2909. doi: 10.1200/JCO.2005.05.0245. PMID: 16782930.
5. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. *N Engl J Med*. 2008;358(1):36–46. doi: 10.1056/NEJMoa073149. PMID: 18172173.
6. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. *J Clin Oncol*. 2008;26(9):1435–1442. doi: 10.1200/JCO.2007.13.9378. PMID: 18349393.
7. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. *J Clin Oncol*. 2014;32(31):3520–3526. doi: 10.1200/JCO.2013.54.1011. Epub 2014 Oct 6. Erratum in: *J Clin Oncol*. 2015;33(12):1416. PMID: 25287828.
8. Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. *Ann Oncol*. 2008;19(8):1450–1457. doi: 10.1093/annonc/mdn166. Epub 2008 Jun 16. PMID: 18558665.
9. Hall PS, Swinson D, Cairns DA, et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2021;7(6):869–877. doi: 10.1001/jamaoncol.2021.0848. Erratum in: *JAMA Oncol*. 2021;7(8):1249. PMID: 33983395; PMID: PMC8120440.
10. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *J Clin Oncol*. 2006;24(31):4991–4997. doi: 10.1200/JCO.2006.06.8429. PMID: 17075117.
11. Shah M, Janjigian YY, Stoller R, et al. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. *J Clin Oncol*. 2015 Nov 20;33(33):3874–9. doi: 10.1200/JCO.2015.60.7465. PMID: 26438119.
12. Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2020;6(10):1571–1580. doi: 10.1001/jamaoncol.2020.3370. PMID: 32880601; PMID: PMC7489405.
13. Wainberg ZA, Shitara K, Van Cutsem E, et al. Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial. *JCO* 40, 243–243(2022). doi: 10.1200/JCO.2022.40.4_suppl.243.
14. Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*. 2021;398(10294):27–40. doi: 10.1016/S0140-6736(21)00797-2. Epub 2021 Jun 5. PMID: 34102137; PMID: PMC8436782.
15. Janjigian YY, Ajani JA, Moehler M, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. *J Clin Oncol*. 2024 Feb 21;JCO2301601. doi: 10.1200/JCO.23.01601. Epub ahead of print. PMID: 38382001.
16. Shitara K, Moehler MH, Ajani JA, et al. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. *JCO*. 2024;42:306–306. doi: 10.1200/JCO.2024.42.3_suppl.306.
17. Zhao JJ, Yap DWT, Chan YH, et al. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. *J Clin Oncol*. 2022;40(4):392–402. doi: 10.1200/JCO.21.01862. Epub 2021 Dec 3. PMID: 34860570.
18. Shitara K, Ajani JA, Moehler M, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. *Nature*. 2022;603(7903):942–948. doi: 10.1038/s41586-022-04508-4. Epub 2022 Mar 23. PMID: 35322232; PMID: PMC8967713.
19. Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2023;24(11):1181–1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. PMID: 37875143.
20. Xu J, Jiang H, Pan Y, et al. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial. *JAMA*. 2023;330(21):2064–2074. doi: 10.1001/jama.2023.19918. PMID: 38051328; PMID: PMC10698618.
21. Moehler MH, Kato K, Arkenau HT, et al. Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC). *JCO*. 2023;41:286–286. doi: 10.1200/JCO.2023.41.4_suppl.286.
22. Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2022;23(2):234–247. doi: 10.1016/S1470-2045(21)00692-6. Epub 2022 Jan 11. PMID: 35030335.
23. Thuss-Scapientia PC, Kretschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer—a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). *Eur J Cancer*. 2011;47(15):2306–2314. doi: 10.1016/j.ejca.2011.06.002. PMID: 21742485.
24. Kang JH, Lee SI, Lim DH, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. *J Clin Oncol*. 2012;30(13):1513–1518. doi: 10.1200/JCO.2011.39.4585. Epub 2012 Mar 12. Erratum in: *J Clin Oncol*. 2012;30(24):3035. PMID: 22412140.
25. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. *J Clin Oncol*. 2013;31(35):4438–4444. doi: 10.1200/JCO.2012.48.5805. Epub 2013 Nov 4. PMID: 24190112.
26. Ford HE, Marshall A, Bridgewater JA, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised-controlled trial. *Lancet Oncol*. 2014;15(1):78–86. doi: 10.1016/S1470-2045(13)70549-7. Epub 2013 Dec 10. PMID: 24332238.
27. Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet*. 2014;383(9911):31–39. doi: 10.1016/S0140-6736(13)61719-5. Epub 2013 Oct 3. PMID: 24094768.
28. Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol*. 2014;15(11):1224–1235. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17. PMID: 25240821.
29. Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet*. 2018;392(10142):123–133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4. PMID: 29880231.
30. Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. *JAMA Oncol*. 2021;7(6):895–902. doi: 10.1001/jamaoncol.2021.0275. PMID: 33792646; PMID: PMC8017478.
31. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. *J Clin Oncol*. 2020;38(1):1–10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4. PMID: 31682550; PMID: PMC8184060.
32. Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol*. 2022;33(10):1005–1020. doi: 10.1016/j.annonc.2022.07.004. Epub 2022 Jul 29. PMID: 35914639.
33. Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2018;19(11):1437–1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: *Lancet Oncol*. 2018;19(12):e668. PMID: 30355453.
34. Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. *Ann Oncol*. 2018;29(10):2052–2060. doi: 10.1093/annonc/mdy264. PMID: 30052729; PMID: PMC6225815.
35. Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017;390(10111):2461–2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. PMID: 28993052.
36. Chen LT, Satoh T, Ryu MH, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. *Gastric Cancer*. 2020;23(3):510–519. doi: 10.1007/s10120-019-01034-7. Epub 2019 Dec 20. PMID: 31863227; PMID: PMC7165140.
37. Boku N, Satoh T, Ryu MH, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. *Gastric Cancer*. 2021;24(4):946–958. doi: 10.1007/s10120-021-01173-w. Epub 2021 Mar 20. PMID: 33743112; PMID: PMC8205916.